Multiple sclerosis trials recruiting in Michigan

All Multiple sclerosis trials nationally

Cities in Michigan

Recruiting trials in Michigan

• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
  NCT06433752 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Ann Arbor, Detroit, Farmington, Owosso
• A Study of AZD0120 in Autoimmune Diseases
  NCT07295847 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Michigan: Ann Arbor
• A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
  NCT07299019 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Michigan: Rochester Hills
• A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
  NCT06680037 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Ann Arbor
• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
  NCT07225504 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Michigan: Farmington Hills
• A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
  NCT06782490 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Michigan: Southfield
• A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
  NCT06735248 · Phase: Phase 2 · Ages: 18 Years to 55 Years · Sex: All (male and female) · Michigan: Farmington Hills
• AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy
  NCT06063850 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Michigan: Grand Rapids
• Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
  NCT04047628 · Phase: Phase 3 · Ages: 18 Years to 55 Years · Sex: All (male and female) · Michigan: Detroit
• Bringing the Outdoors In: Virtual Nature Walks for Depression in Multiple Sclerosis (MS) Patients
  NCT07392879 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Ann Arbor
• Development of Pain Management JITAI Content in Multiple Sclerosis and Spinal Cord Injury
  NCT07663266 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Ann Arbor
• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
  NCT06846281 · Phase: Phase 3 · Ages: 40 Years to 70 Years · Sex: All (male and female) · Michigan: Farmington Hills, Owosso
• Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis
  NCT04458688 · Phase: Not specified · Ages: 18 Years to 60 Years · Sex: All (male and female) · Michigan: Detroit
• Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
  NCT05269628 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Michigan: Ann Arbor
• Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
  NCT07325292 · Phase: Phase 3 · Ages: 18 Years to 60 Years · Sex: All (male and female) · Michigan: Farmington Hills
• Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
  NCT06655896 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · Michigan: Ann Arbor
• Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
  NCT07623668 · Phase: Phase 3 · Ages: 18 Years to 50 Years · Sex: All (male and female) · Michigan: Livonia
• RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
  NCT07002034 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Michigan: Ann Arbor, Novi
• Study of COYA 302 for the Treatment of ALS
  NCT07161999 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Michigan: Ann Arbor
• Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
  NCT05877963 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Michigan: Farmington
• Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
  NCT03816345 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Detroit